$ 100.92
Key Takeaways
Risk factor
Strong trading liquidity
Profitability factor
Favourable analyst view
About
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r
Target Price
The average target price of ILMN is 107 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
